227 related articles for article (PubMed ID: 24111980)
1. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980
[TBL] [Abstract][Full Text] [Related]
2. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):531-44. PubMed ID: 24111983
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study.
Findling RL; Atkinson S; Bachinsky M; Raiter Y; Abreu P; Ianos C; Chappell P
J Child Adolesc Psychopharmacol; 2022 Apr; 32(3):143-152. PubMed ID: 35394365
[No Abstract] [Full Text] [Related]
4. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
DelBello MP; Versavel M; Ice K; Keller D; Miceli J
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):491-9. PubMed ID: 18928413
[TBL] [Abstract][Full Text] [Related]
5. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
9. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
[TBL] [Abstract][Full Text] [Related]
10. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
Potkin SG; Keck PE; Segal S; Ice K; English P
J Clin Psychopharmacol; 2005 Aug; 25(4):301-10. PubMed ID: 16012271
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.
Keck PE; Versiani M; Warrington L; Loebel AD; Horne RL
J Clin Psychiatry; 2009 Jun; 70(6):844-51. PubMed ID: 19573482
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
14. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
Patkar A; Gilmer W; Pae CU; Vöhringer PA; Ziffra M; Pirok E; Mulligan M; Filkowski MM; Whitham EA; Holtzman NS; Thommi SB; Logvinenko T; Loebel A; Masand P; Ghaemi SN
PLoS One; 2012; 7(4):e34757. PubMed ID: 22545088
[TBL] [Abstract][Full Text] [Related]
15. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
18. 26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic).
Atkinson S; Bachinsky M; Raiter Y; Abreu P; Ianos C; Chappell P; Findling RL
J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):453-458. PubMed ID: 36282771
[No Abstract] [Full Text] [Related]
19. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
[TBL] [Abstract][Full Text] [Related]
20. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Karayal ON; Glue P; Bachinsky M; Stewart M; Chappell P; Kolluri S; Cavus I
J Psychiatr Pract; 2011 Mar; 17(2):100-9. PubMed ID: 21430488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
